Regorafenib-Associated Acute Pancreatitis Diagnosed on 18F-FDG PET/CT

ABSTRACTA 23-year-old man with metastatic osteosarcoma, with disease progression on conventional chemotherapy, was treated with regorafenib, a multikinase inhibitor. After treatment for 6 months with regorafenib, F-FDG PET/CT scan demonstrated FDG uptake in a necrotic space-occupying lesion involvin...

Full description

Saved in:
Bibliographic Details
Published in:Clinical nuclear medicine 2021-05, Vol.46 (5), p.e256-e257
Main Authors: Pereira, Melvika, Prakash, Anjali, Puranik, Ameya D., Purandare, Nilendu, Shah, Sneha, Agrawal, Archi, Rangarajan, Venkatesh
Format: Article
Language:English
Subjects:
Fluorodeoxyglucose F18
Humans
Male
Osteosarcoma - drug therapy
Osteosarcoma - pathology
Pancreatitis - chemically induced
Pancreatitis - diagnostic imaging
Phenylurea Compounds - adverse effects
Phenylurea Compounds - therapeutic use
Positron Emission Tomography Computed Tomography
Pyridines - adverse effects
Pyridines - therapeutic use
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACTA 23-year-old man with metastatic osteosarcoma, with disease progression on conventional chemotherapy, was treated with regorafenib, a multikinase inhibitor. After treatment for 6 months with regorafenib, F-FDG PET/CT scan demonstrated FDG uptake in a necrotic space-occupying lesion involving tail of pancreas. After imaging, patient described symptoms of epigastric pain with elevated serum amylase and lipase levels, confirming diagnosis of regorafenib-induced pancreatitis, because patient had no other causative factors of pancreatitis. Physicians should be aware of rare and possibly clinically silent adverse effects of tyrosine kinase inhibitors, like acute pancreatitis, and recognize the F-FDG PET/CT findings to guide appropriate clinical management.
ISSN:0363-9762
1536-0229
DOI:10.1097/RLU.0000000000003449